Self Regional Healthcare

As an affiliate of the Medical University of South Carolina, Self Regional Healthcare is an active NCORP site. Self Regional Healthcare is currently active on the following clinical trials addressing various cancer types. Ask your health care provider for more information.

All Disease Sites

• A212102: Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  To provide a blinded reference set of cancer vs. non-cancer blood samples that will be used to validate assays for inclusion in a prospective clinical trial focused on utility of blood-based multi-cancer early detection.
• URCC-21038: Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
  This is a Prospective Observational Cohort Study, designed specifically to investigate racial differences in toxicities and treatment outcomes of cancer patients treated with immune checkpoint inhibitors (ICIs).

Breast

• A012103: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
  To evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab.
• CCTG MA.39: Testing regional radiation therapy in patients with low risk breast cancer
  This trial studies if not giving regional radiotherapy is just as good as using regional radiotherapy in keeping breast cancer from coming back in patients with estrogen receptor-positive, HER2-negative, node-positive low-risk breast cancer who have undergone breast conserving surgery or mastectomy.

Genitourinary

• GU009: Two studies for patients with high risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a high gene risk score
  This trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score.
• GU010: Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score
  This trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body.
• GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
  To determine whether the addition of stereotactic ablative radiotherapy to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma.
• GU013: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  To compare metastasis-free survival, using conventional imaging, between men with high-risk prostate cancer randomized to ultrahypofractionation stereotactic body radiotherapy to those randomized to moderate hypofractionation and conventional fractionation.

Head & Neck

• HN009: Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
  This trial compares whether low-dose cisplatin given weekly with radiation is better tolerated than high-dose cisplatin given every three weeks with radiation therapy for the treatment of head & neck cancer that has spread to other places in the body.

Thoracic/Lung

• CTIU2317-A082304-S2402: Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
  To compare the 3-year real-world event-free survival rate and overall survival between perioperative and adjuvant immunotherapy-based treatment for patients with resectable non-small cell lung cancer.